GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Zynex Inc (NAS:ZYXI) » Definitions » Cyclically Adjusted Revenue per Share

Zynex (ZYXI) Cyclically Adjusted Revenue per Share : $2.02 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Zynex Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Zynex's adjusted revenue per share for the three months ended in Dec. 2023 was $1.392. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $2.02 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Zynex's average Cyclically Adjusted Revenue Growth Rate was 31.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 30.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 23.90% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 13.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Zynex was 30.00% per year. The lowest was -81.10% per year. And the median was 8.30% per year.

As of today (2024-04-27), Zynex's current stock price is $11.21. Zynex's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $2.02. Zynex's Cyclically Adjusted PS Ratio of today is 5.55.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zynex was 30.93. The lowest was 0.18. And the median was 4.38.


Zynex Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Zynex's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zynex Cyclically Adjusted Revenue per Share Chart

Zynex Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.79 0.92 1.20 1.54 2.02

Zynex Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.54 1.65 1.77 1.90 2.02

Competitive Comparison of Zynex's Cyclically Adjusted Revenue per Share

For the Medical Distribution subindustry, Zynex's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zynex's Cyclically Adjusted PS Ratio Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Zynex's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Zynex's Cyclically Adjusted PS Ratio falls into.



Zynex Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zynex's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.392/129.4194*129.4194
=1.392

Current CPI (Dec. 2023) = 129.4194.

Zynex Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.092 99.695 0.119
201406 0.039 100.560 0.050
201409 0.128 100.428 0.165
201412 0.064 99.070 0.084
201503 0.093 99.621 0.121
201506 0.089 100.684 0.114
201509 0.078 100.392 0.101
201512 0.079 99.792 0.102
201603 0.101 100.470 0.130
201606 0.096 101.688 0.122
201609 0.105 101.861 0.133
201612 0.085 101.863 0.108
201703 0.098 102.862 0.123
201706 0.138 103.349 0.173
201709 0.185 104.136 0.230
201712 0.215 104.011 0.268
201803 0.182 105.290 0.224
201806 0.201 106.317 0.245
201809 0.218 106.507 0.265
201812 0.252 105.998 0.308
201903 0.248 107.251 0.299
201906 0.276 108.070 0.331
201909 0.315 108.329 0.376
201912 0.378 108.420 0.451
202003 0.405 108.902 0.481
202006 0.508 108.767 0.604
202009 0.513 109.815 0.605
202012 0.653 109.897 0.769
202103 0.630 111.754 0.730
202106 0.793 114.631 0.895
202109 0.891 115.734 0.996
202112 1.026 117.630 1.129
202203 0.755 121.301 0.806
202206 0.921 125.017 0.953
202209 1.068 125.227 1.104
202212 1.308 125.222 1.352
202303 1.126 127.348 1.144
202306 1.213 128.729 1.220
202309 1.383 129.860 1.378
202312 1.392 129.419 1.392

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Zynex  (NAS:ZYXI) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Zynex's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=11.21/2.02
=5.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zynex was 30.93. The lowest was 0.18. And the median was 4.38.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Zynex Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Zynex's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Zynex (ZYXI) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Zynex Inc (NAS:ZYXI) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
N/A
Address
9555 Maroon Circle, Englewood, CO, USA, 80112
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufacture, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. it also develops and markets medical devices for non-invasive cardiac monitoring, the products of which are under development. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave and others.
Executives
Daniel J Moorhead officer: Chief Financial Officer 9777 PYRAMID CT, STE 100, ENGLEWOOD CO 80112
Anna Lucsok officer: See Remarks 9555 MAROON CIRCLE, ENGLEWOOD CO 80112
Thomas Sandgaard director, 10 percent owner, officer: President, CEO and Chairman 10506 KALAHARI CT., LONE TREE CO 80124
Neil Friery officer: See Remarks C/O ZYNEX, INC. 9555 MAROON CIRCLE, ENGLEWOOD CO 80112
Joshua R. Disbrow director AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Barry D Michaels director 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Michael D Cress director 3409 ESPERANZA CROSSING SUITE 7110, AUSTIN TX 78758
Sandgaard Holdings Llc 10 percent owner 9555 MAROON CIRCLE, ENGLEWOOD CO 80112
Giuseppe Papandrea officer: Chief Operating Officer C/O ZYNEX, INC. 9555 MAROON CIRCLE, ENGLEWOOD CO 80112